Lipfendra (Enlicitide): The World's First Oral PCSK9 Inhibitor Approved by FDA

　　On July 16,2026,Merck announced that its innovative lipid-lowering agent Lipfendra(generic name:enlicitide)has received approval from the U.S.Food and Drug Administration(FDA).As the first oral PCSK9 inhibitor ever approved,Lipfendra represents a paradigm shift in cholesterol management—transitioning from injectable therapies to a convenient once-daily tablet.

　　Lipfendra is indicated as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol(LDL-C,commonly known as"bad cholesterol")levels in adults with hypercholesterolemia,including patients with heterozygous familial hypercholesterolemia(HeFH).The recommended dosage is one 20 mg tablet taken orally once daily in the morning on an empty stomach.The tablet must be swallowed whole without splitting,crushing,or chewing,and patients should wait at least 30 minutes before eating or drinking.

　　Mechanistically,Lipfendra is a macrocyclic peptide that inhibits PCSK9(proprotein convertase subtilisin/kexin type 9).Under normal physiological conditions,PCSK9 binds to LDL receptors(LDLR)on the surface of hepatocytes and promotes their degradation,thereby reducing the liver's capacity to clear LDL-C from the bloodstream.Enlicitide binds directly to PCSK9,preventing its interaction with LDL receptors.This preserves a greater number of functional LDL receptors on hepatocyte surfaces,enhancing hepatic uptake and clearance of circulating LDL-C,ultimately resulting in substantial reductions in serum LDL-C levels.

　　The approval of Lipfendra was primarily supported by data from the CORALreef Phase 3 clinical trial program.In the CORALreef HeFH study,treatment with Lipfendra for 24 weeks achieved a 59%reduction in LDL-C compared with placebo in patients with heterozygous familial hypercholesterolemia.The CORALreef Lipids study demonstrated an approximately 56%LDL-C reduction in the general hypercholesterolemia population.Additionally,the drug significantly improved multiple lipid parameters including non-HDL cholesterol,apolipoprotein B,and lipoprotein(a),with a safety profile comparable to placebo and no meaningful difference in adverse events.

　　Compared with previously approved PCSK9 inhibitors—which all require subcutaneous injection every two weeks or monthly—Lipfendra's most significant advancement lies in delivering potent lipid-lowering efficacy through a once-daily oral tablet.This innovation in drug delivery substantially improves long-term treatment convenience and adherence.It offers a practical intensified therapy option particularly for patients who have inadequate responses to statins,difficulty adhering to injectable regimens,or who cannot achieve lipid targets through lifestyle modifications alone.

　　Regarding pricing,Merck has set the daily cost of Lipfendra at USD 10.50(based on a 30-day treatment course).Industry analysts project global sales of approximately USD 370 million by 2027,with the potential to exceed USD 1 billion in annual revenue by 2029.

　　It should be noted that while Lipfendra has demonstrated robust efficacy in lowering LDL-C and improving multiple lipid parameters,its long-term benefits in reducing cardiovascular event rates and mortality remain under further investigation.Patients using this medication should continue to maintain a healthy diet and regular physical activity,and should develop individualized treatment plans under the guidance of qualified healthcare professionals.